- Home
- ABCB vs AKRO Comparison
ABCB vs AKRO Comparison
Compare ABCB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABCB
- AKRO
- Stock Information
- Founded
- ABCB 1971
- AKRO 2017
- Country
- ABCB United States
- AKRO United States
- Employees
- ABCB N/A
- AKRO N/A
- Industry
- ABCB Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ABCB Finance
- AKRO Health Care
- Exchange
- ABCB Nasdaq
- AKRO Nasdaq
- Market Cap
- ABCB 4.4B
- AKRO 3.9B
- IPO Year
- ABCB N/A
- AKRO 2019
- Fundamental
- Price
- ABCB $67.74
- AKRO $51.77
- Analyst Decision
- ABCB Buy
- AKRO Strong Buy
- Analyst Count
- ABCB 6
- AKRO 6
- Target Price
- ABCB $69.83
- AKRO $82.50
- AVG Volume (30 Days)
- ABCB 339.9K
- AKRO 1.7M
- Earning Date
- ABCB 07-28-2025
- AKRO 08-08-2025
- Dividend Yield
- ABCB 1.18%
- AKRO N/A
- EPS Growth
- ABCB 31.20
- AKRO N/A
- EPS
- ABCB 5.38
- AKRO N/A
- Revenue
- ABCB $1,100,260,000.00
- AKRO N/A
- Revenue This Year
- ABCB $12.06
- AKRO N/A
- Revenue Next Year
- ABCB $6.18
- AKRO N/A
- P/E Ratio
- ABCB $12.59
- AKRO N/A
- Revenue Growth
- ABCB 13.98
- AKRO N/A
- 52 Week Low
- ABCB $48.21
- AKRO $21.02
- 52 Week High
- ABCB $74.56
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ABCB 73.92
- AKRO 48.51
- Support Level
- ABCB $64.30
- AKRO $51.08
- Resistance Level
- ABCB $67.22
- AKRO $57.35
- Average True Range (ATR)
- ABCB 1.29
- AKRO 2.17
- MACD
- ABCB 0.54
- AKRO -0.82
- Stochastic Oscillator
- ABCB 94.96
- AKRO 8.17
About ABCB Ameris Bancorp
Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the Premium Finance Division. The company generates majority of its revenue from the banking division. Ameris intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.